PURPOSE: Tumor cell migration and metastasis share many similarities with leukocyte trafficking, which is critically regulated by chemokines and their receptors. CXCR4 is the most widely expressed chemokine receptor in many different types of cancer and has been linked to tumor dissemination and poor prognosis. Several CXCR4 antagonists have been synthesized. A totally novel approach to discover chemokine receptor antagonists is the use of bacteria. Bacteria produce chemokine receptor inhibitors to prevent neutrophil extravasation and migration toward the infection site to escape clearance by innate immune cells. The aim of the current study was to find and identify the mechanism of a bacterial protein that specifically targets CXCR4, a chemokine receptor shared by neutrophils and cancer cells. EXPERIMENTAL DESIGN: Several staphylococcal proteins were screened for their capacity to prevent binding of a function-blocking antibody against CXCR4. RESULTS: Staphylococcal superantigen-like 10 was found to bind CXCR4 expressed on human T acute lymphoblastic leukemia, lymphoma, and cervical carcinoma cell lines. It potently inhibited CXCL12-induced calcium mobilization and cell migration. CONCLUSIONS: Staphylococcal superantigen-like 10 is a potential lead in the development of new anticancer compounds preventing metastasis by targeting CXCR4.
PURPOSE:Tumor cell migration and metastasis share many similarities with leukocyte trafficking, which is critically regulated by chemokines and their receptors. CXCR4 is the most widely expressed chemokine receptor in many different types of cancer and has been linked to tumor dissemination and poor prognosis. Several CXCR4 antagonists have been synthesized. A totally novel approach to discover chemokine receptor antagonists is the use of bacteria. Bacteria produce chemokine receptor inhibitors to prevent neutrophil extravasation and migration toward the infection site to escape clearance by innate immune cells. The aim of the current study was to find and identify the mechanism of a bacterial protein that specifically targets CXCR4, a chemokine receptor shared by neutrophils and cancer cells. EXPERIMENTAL DESIGN: Several staphylococcal proteins were screened for their capacity to prevent binding of a function-blocking antibody against CXCR4. RESULTS: Staphylococcal superantigen-like 10 was found to bind CXCR4 expressed on human T acute lymphoblastic leukemia, lymphoma, and cervical carcinoma cell lines. It potently inhibited CXCL12-induced calcium mobilization and cell migration. CONCLUSIONS: Staphylococcal superantigen-like 10 is a potential lead in the development of new anticancer compounds preventing metastasis by targeting CXCR4.
Authors: A Müller; B Homey; H Soto; N Ge; D Catron; M E Buchanan; T McClanahan; E Murphy; W Yuan; S N Wagner; J L Barrera; A Mohar; E Verástegui; A Zlotnik Journal: Nature Date: 2001-03-01 Impact factor: 49.962
Authors: Russell S Taichman; Carlton Cooper; Evan T Keller; Kenneth J Pienta; Norton S Taichman; Laurie K McCauley Journal: Cancer Res Date: 2002-03-15 Impact factor: 12.701
Authors: J Ross Fitzgerald; Sean D Reid; Eeva Ruotsalainen; Timothy J Tripp; MengYao Liu; Robert Cole; Pentti Kuusela; Patrick M Schlievert; Asko Järvinen; James M Musser Journal: Infect Immun Date: 2003-05 Impact factor: 3.441
Authors: Bent Postma; Miriam J Poppelier; Joost C van Galen; Eric R Prossnitz; Jos A G van Strijp; Carla J C de Haas; Kok P M van Kessel Journal: J Immunol Date: 2004-06-01 Impact factor: 5.422
Authors: Kirsten J Koymans; Louris J Feitsma; T Harma C Brondijk; Piet C Aerts; Eddie Lukkien; Philip Lössl; Kok P M van Kessel; Carla J C de Haas; Jos A G van Strijp; Eric G Huizinga Journal: Proc Natl Acad Sci U S A Date: 2015-08-17 Impact factor: 11.205
Authors: Jovanka Bestebroer; Piet C Aerts; Suzan H M Rooijakkers; Manoj K Pandey; Jörg Köhl; Jos A G van Strijp; Carla J C de Haas Journal: Cell Microbiol Date: 2010-10 Impact factor: 3.715
Authors: B W Bardoel; R Vos; T Bouman; P C Aerts; J Bestebroer; E G Huizinga; T H C Brondijk; J A G van Strijp; C J C de Haas Journal: J Mol Med (Berl) Date: 2012-06-20 Impact factor: 4.599